Biotech Industry Look to Benefit From the Introduction of the High Technology Small Business Research Incentives Act
September 28 2012 - 8:20AM
Marketwired
The Biotechnology Industry has seen increased investor interest in
2012 as it continues to impress with strong gains. The iShares
NASDAQ Biotechnology Index ETF (IBB) has gained over 35 percent
this year, more than double the S&P 500 Index's gain of 15
percent. New legislation, increased mergers & acquisition
activity as a result of major patent expirations have all been
contributing factors to the industry's rapid rise in 2012. Five
Star Equities examines the outlook for companies in the Biotech
Industry and provides equity research on AEterna Zentaris Inc.
(NASDAQ: AEZS) and Cell Therapeutics Inc. (NASDAQ: CTIC).
Access to the full company reports can be found at:
www.FiveStarEquities.com/AEZS
www.FiveStarEquities.com/CTIC
The Biotechnology Industry Organization (BIO) has recently
praised the introduction of the High Technology Small Business
Research Incentives Act. The new legislation would allow investors
of joint venture R&D projects to utilize the losses and tax
credits.
"Through the tax code, Congress historically has provided
opportunities that encourage private investment in pre-revenue,
R&D-intensive companies. The early growth of the biotech
industry in the 1980s was due in part to the ability of investors
to support projects aimed at finding new cures and treatments
through similar joint ventures. This legislation will help spur
greater private investment in biotech and other R&D intensive
industries," BIO's President and CEO Jim Greenwood said in a
statement.
Five Star Equities releases regular market updates on the
Biotech Industry so investors can stay ahead of the crowd and make
the best investment decisions to maximize their returns. Take a few
minutes to register with us free at www.FiveStarEquities.com and
get exclusive access to our numerous stock reports and industry
newsletters.
Aeterna Zentaris is an oncology and endocrinology drug
development company currently investigating treatments for various
unmet medical needs. The Company's pipeline encompasses compounds
at all stages of development, from drug discovery through to
marketed products. The company recently reported that Fast Track
designation had not been granted from the FDA for AEZS-130.
Cell Therapeutics is a biopharmaceutical company committed to
developing an integrated portfolio of oncology products aimed at
making cancer more treatable. The company recently reported
positive results from their phase 1 study of its highly selective
oral JAK2 inhibitor pacritinib, or SB1518.
Five Star Equities provides Market Research focused on equities
that offer growth opportunities, value, and strong potential
return. We strive to provide the most up-to-date market activities.
We constantly create research reports and newsletters for our
members. Five Star Equities has not been compensated by any of the
above-mentioned companies. We act as an independent research portal
and are aware that all investment entails inherent risks. Please
view the full disclaimer at:
www.FiveStarEquities.com/disclaimer
Add to Digg Bookmark with del.icio.us Add to Newsvine
Contact: Five Star Equities Email Contact
Aeterna Zentaris (NASDAQ:AEZS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Aeterna Zentaris (NASDAQ:AEZS)
Historical Stock Chart
From Jul 2023 to Jul 2024